Scott Rocklage has been Managing Partner of 5AM Ventures since 2004. Novartis Venture Fund, Kleiner Perkins, Alexandria Venture Investments, RA Capital Management, Sanofi Ventures, and 5AM Ventures have all taken part in generating money for Series A. Expansion Therapeutics raises money for Series A financing for combating genetic disorders. DM1, or Myotonic dystrophy type I, is one of the disorders that is being funded.
DM1 is the top cause of muscular dystrophy in adults. Expansion Therapeutics has added over $50 million to its cause in order to fight the disease. When RNA reaches high levels within the cells, symptoms of the disease show themselves. Consequently, the heart, muscles, central nervous system, gastrointestinal system, respiratory system, and the hormonal system all start becoming defective.
Sadly, the medical community doesn’t have a good treatment for DM1. That is why funding is needed for this particular disease. It doesn’t just affect families now, it affects succeeding generations. Expansion Therapeutics makes medications that challenge RNA illnesses. They particularly deal with repeat disorders in which hereditary illnesses don’t respond well to current medical treatments.
Scott Rocklage earned his Bachelor of Science degree in Chemistry at the University of California, Berkeley. He then received his Ph.D. in Chemistry from MIT. He has over 30 years of experience in healthcare management, as well as research experience.
Dr. Scott Rocklage has given FDA approval on Teslascan, Omniscan, and Cubicin medications. Over 30 U.S. patents have been co-invented or invented by him. He was once the CEO and Chairman of Cubist Pharmaceuticals and CEO and President of Nycomed Salutar. Currently, he is the Board Chairman for Rennovia, Kinestral, and Cidara. And, he now works in the Boston, Massachusetts office of 5AM Ventures.
Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.